profit from every CHF 100 of sales.
CHF 0CHF 100
Lonza Group
CHF 666.00+0.00% today
+27.1% in 1 year
1-year low CHF 466.701-year high CHF 672.40
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Lonza Group sold, what it kept, and what it did with the cash.
Sales went from CHF 6.22 billion in 2022 to CHF 6.53 billion in 2025, with -CHF 275 million of profit last year.
SalesProfit
Lonza Group vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from CHF 100 of sales | Sales growth a year | Price per CHF 1 of profit |
|---|---|---|---|
| Lonza Group | No profit yet | ||
 Thermo Fisher Scientific | 38.7× · Expensive | ||
 Danaher | 45.4× · Expensive | ||
 Waters | 140.8× · Very expensive | ||
 WuXi AppTec | 25.8× · Fair price |
AI analysis
An AI analyst reads Lonza Group's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 6,223 | 6,717 | 5,480 | 6,531 | |
| 2,438 | 1,948 | 1,793 | 2,309 | |
| 1,357 | 873 | 879 | 1,358 | |
| 2,107 | 1,504 | 1,495 | 2,077 | |
| 1,215 | 654 | 636 | -275 | |
| 16.34 | 8.88 | 8.92 | – | |
| 39.2% | 29.0% | 32.7% | 35.4% | |
| 21.8% | 13.0% | 16.0% | 20.8% | |
| 19.5% | 9.7% | 11.6% | -4.2% |
Balance sheet
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 17,356 | 16,848 | 19,733 | 17,907 |
| Cash | 1,339 | 1,468 | 1,111 | 719 |
| Total debt | 2,587 | 3,132 | 5,120 | 4,540 |
| Total liabilities | 6,691 | 7,336 | 10,345 | 9,941 |
| 10,597 | 9,452 | 9,328 | 7,913 | |
| 74 | 74 | 71 | – | |
| 9.7% | 6.0% | 5.0% | 8.6% | |
| 11.5% | 6.9% | 6.8% | -3.5% |
Cash flow
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,020 | 1,388 | 1,274 | 1,156 | |
| 1,872 | 1,682 | 1,417 | 1,373 | |
| -852 | -294 | -143 | -217 | |
| Dividends paid | 228 | 263 | 288 | 282 |
| 58 | 1,200 | 769 | 518 | |
| 32 | 21 | 41 | 57 |
Valuation
- –
- –
- –
- 5.9×
- 7.1×
- –
- 24.2×
- -0.5%
- -0.6%
- 0.6%
Profitability
- 35.4%
- 20.8%
- -4.2%
- –
- 8.6%
- 7.3%
- –
- –
- –
- –
Growth
- +1.6%
- –
- –
- –
- −1.9%
Financial health
- 1.8×
- 0.57
- –
- 7.8×
- 1.89
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 36%of 952
Top 22%of 883
Bottom 18%of 870
Bottom 36%of 985
0.6%of the share price, paid each year
On $1,000 invested$6a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
27No pass
Philip Fisher
39No pass
Peter Lynch
27No pass
Joel Greenblatt
3No pass
Charlie Munger
36No pass
Terry Smith
30No pass
Questions about Lonza Group
Is Lonza Group a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Lonza Group AI analysis
What does Lonza Group do?
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It is in Diagnostics & Research, based in Basel, Switzerland, with 20,000 employees.
Does Lonza Group pay a dividend?
Yes. At today's price the dividend is 0.6% a year. In 2025 it paid out CHF 282 million in dividends.
Is Lonza Group stock halal?
Yes. Lonza Group passes our halal screen: its business is permitted and its debt is 10% of its market value, under the 30% limit. How we check
How has Lonza Group stock done over the past year?
Up 27.1% over the past twelve months, to CHF 666.00. It traded between CHF 466.70 and CHF 672.40, close to its high.
Who are Lonza Group's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Danaher, Waters and WuXi AppTec. The peers table on this page compares their profit, growth and price with Lonza Group's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.